Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000449 · ClinicalTrials.gov registry record · Phase 4
Behavior and Naltrexone Treatment for Alcoholics
A Phase 4 study, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- Completed
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
NCT00000449: Completed Phase 4 study, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
NCT00000449 is a Phase 4 study that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 160 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000449, a Phase 4 study, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
Study Summary
The study's purpose is to improve alcoholism treatment by investigating the combined effectiveness of a psychotherapy (Coping Skills Training and Cue Exposure Treatment - CSTCET) with naltrexone in a randomized clinical trial. Individuals will receive 2 weeks of CSTCET or a control treatment as inpatients followed by 12 consecutive weeks of receiving either naltrexone or placebo as outpatients. Followups at 24, 48, and 72 weeks after treatment is completed.
Interventions
- BEHAVIORAL cognitive behavioral therapy
- DRUG naltrexone (Revia)
- BEHAVIORAL cue exposure treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Est. Completion | 2000-03 |
| Phase | Phase 4 |
What the finished NCT00000449 record still lists
NCT00000449 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 3 interventions - of which cognitive behavioral therapy is the first listed.
NCT00000449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000449 about?
NCT00000449 is a clinical study titled "Behavior and Naltrexone Treatment for Alcoholics". The study's purpose is to improve alcoholism treatment by investigating the combined effectiveness of a psychotherapy (Coping Skills Training and Cue Exposure Treatment - CSTCET) with naltrexone in a randomized clinical trial. Individuals will receive 2 weeks of CSTCET or a control treatment as inpa...
What is the current status of trial NCT00000449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. Estimated completion is 2000-03.
What interventions are being tested in trial NCT00000449?
The interventions under investigation include: cognitive behavioral therapy (BEHAVIORAL), naltrexone (Revia) (DRUG), cue exposure treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT00000449?
This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000449's enrollment target sits among peer trials
160 507th of 2000 higher than 1,485 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)